© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 22, 1697-1703,
November 20, 2002
© 2002 Oxford University Press
ARTICLE |
Assessment of Plasma DNA Levels, Allelic Imbalance, and CA 125 as Diagnostic Tests for Cancer
H. W. Chang, G. Singer, S. K. R. Cho, L. J. Sokoll, R. Roden, Z. Zhang (Department of Pathology), S. M. Lee, S. N. Goodman (The Oncology Center), F. J. Montz (Departments of Gynecology and Obstetrics), D. W. Chan (Department of Pathology and The Oncology Center), R. J. Kurman, I. M. Shih (Departments of Pathology, Gynecology, and Obstetrics) The Johns Hopkins University School of Medicine, Baltimore, MD.
Correspondence to: Ie-Ming Shih, M.D., Ph.D., Department of Pathology, The Johns Hopkins University School of Medicine, 418 N. Bond St., B-315, Baltimore, MD 21231 (e-mail: ishih{at}jhmi.edu).
Background: Allelic imbalance (AI), the loss or gain of chromosomal regions, is found in many cancers. AI can be detected in genomic tumor DNA released into the blood after necrosis or apoptosis. We evaluated plasma DNA concentration, allelic status in plasma DNA, and serum CA 125 level as screening tests for ovarian and other cancers. Methods: Plasma samples were obtained from 330 women (44 normal healthy control individuals, 122 patients with various cancers, and 164 control patients with non-neoplastic diseases). Plasma DNA concentration was determined in all samples. Allelic status was determined by digital single nucleotide polymorphism (SNP) analysis with eight SNP markers in plasma DNA from 54 patients with ovarian cancer and 31 control patients. CA 125 was determined in 63 samples. Receiver-operating characteristic (ROC) curves were plotted, and the areas under the ROC curves—a measure of the overall ability of a diagnostic test with multiple cutoffs to distinguish between diseased and nondiseased individuals—were determined. Results: The area under the ROC curve for plasma DNA concentration was 0.90 for patients with neoplastic disease versus healthy control individuals and 0.74 for patients with neoplastic diseases versus control patients with non-neoplastic diseases. For control subjects given a specificity of 100% (95% confidence interval [CI] = 92% to 100%), the highest sensitivity achieved was 57% (95% CI = 49% to 67%). AI in at least one SNP was found in 87% (95% CI = 60% to 98%) of patients with stage I/II ovarian cancer and 95% (95% CI = 83% to 99%) of patients with stage III/IV ovarian cancer, but AI was not found in 31 patients with non-neoplastic diseases (specificity = 100%, 95% CI = 89% to 100%). The area under the ROC curve assessing AI was 0.95. Combining the serum CA 125 level with the plasma DNA concentration increased the area under the ROC curve from 0.78 (CA 125 alone) to 0.84. Conclusion: Plasma DNA concentration may not be sensitive or specific enough for cancer screening or diagnosis, even when combined with CA 125. AI was detected with high specificity in plasma DNA from patients with ovarian cancer and should be studied further as a screening tool.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Salani, B. Davidson, M. Fiegl, C. Marth, E. Muller-Holzner, G. Gastl, H.-Y. Huang, J.-C. Hsiao, H.-S. Lin, T.-L. Wang, et al. Measurement of Cyclin E Genomic Copy Number and Strand Length in Cell-Free DNA Distinguish Malignant versus Benign Effusions Clin. Cancer Res., October 1, 2007; 13(19): 5805 - 5809. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Wang, L. Wang, C. Briggs, E. Sicinska, S. M. Gaston, H. Mamon, M. H. Kulke, R. Zamponi, M. Loda, E. Maher, et al. DNA Degradation Test Predicts Success in Whole-Genome Amplification from Diverse Clinical Samples J. Mol. Diagn., September 1, 2007; 9(4): 441 - 451. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. M. D. Lo, F. M. F. Lun, K. C. A. Chan, N. B. Y. Tsui, K. C. Chong, T. K. Lau, T. Y. Leung, B. C. Y. Zee, C. R. Cantor, and R. W. K. Chiu From the Cover: Digital PCR for the molecular detection of fetal chromosomal aneuploidy PNAS, August 7, 2007; 104(32): 13116 - 13121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Hagiwara, L. E. Mechanic, G. E. Trivers, H. L. Cawley, M. Taga, E. D. Bowman, K. Kumamoto, P. He, M. Bernard, S. Doja, et al. Quantitative Detection of p53 Mutations in Plasma DNA from Tobacco Smokers Cancer Res., August 15, 2006; 66(16): 8309 - 8317. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hanley, K. M. Rieger-Christ, D. Canes, N. R. Emara, A. P. Shuber, K. A. Boynton, J. A. Libertino, and I. C. Summerhayes DNA Integrity Assay: A Plasma-Based Screening Tool for the Detection of Prostate Cancer Clin. Cancer Res., August 1, 2006; 12(15): 4569 - 4574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Li, L. Harris, H. Mamon, M. H. Kulke, W.-H. Liu, P. Zhu, and G. Mike Makrigiorgos Whole Genome Amplification of Plasma-Circulating DNA Enables Expanded Screening for Allelic Imbalance in Plasma J. Mol. Diagn., February 1, 2006; 8(1): 22 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Herrera, S. Raja, W. E. Gooding, T. El-Hefnawy, L. Kelly, J. D. Luketich, and T. E. Godfrey Quantitative Analysis of Circulating Plasma DNA as a Tumor Marker in Thoracic Malignancies Clin. Chem., January 1, 2005; 51(1): 113 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. I. de Caceres, C. Battagli, M. Esteller, J. G. Herman, E. Dulaimi, M. I. Edelson, C. Bergman, H. Ehya, B. L. Eisenberg, and P. Cairns Tumor Cell-Specific BRCA1 and RASSF1A Hypermethylation in Serum, Plasma, and Peritoneal Fluid from Ovarian Cancer Patients Cancer Res., September 15, 2004; 64(18): 6476 - 6481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Gifford, J. Paul, P. A. Vasey, S. B. Kaye, and R. Brown The Acquisition of hMLH1 Methylation in Plasma DNA after Chemotherapy Predicts Poor Survival for Ovarian Cancer Patients Clin. Cancer Res., July 1, 2004; 10(13): 4420 - 4426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-S. Wong, D. L.-W. Kwong, J. S.-T. Sham, W. I. Wei, Y.-L. Kwong, and A. P.-W. Yuen Quantitative Plasma Hypermethylated DNA Markers of Undifferentiated Nasopharyngeal Carcinoma Clin. Cancer Res., April 1, 2004; 10(7): 2401 - 2406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Sozzi, D. Conte, M. Leon, R. Cirincione, L. Roz, C. Ratcliffe, E. Roz, N. Cirenei, M. Bellomi, G. Pelosi, et al. Quantification of Free Circulating DNA As a Diagnostic Marker in Lung Cancer J. Clin. Oncol., November 1, 2003; 21(21): 3902 - 3908. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Stemmer, M. Beau-Faller, E. Pencreac'h, E. Guerin, A. Schneider, D. Jaqmin, E. Quoix, M.-P. Gaub, and P. Oudet Use of Magnetic Beads for Plasma Cell-free DNA Extraction: Toward Automation of Plasma DNA Analysis for Molecular Diagnostics Clin. Chem., November 1, 2003; 49(11): 1953 - 1955. [Full Text] [PDF]
|
|
|
|
|
|
B. G. Wang, H.-Y. Huang, Y.-C. Chen, R. E. Bristow, K. Kassauei, C.-C. Cheng, R. Roden, L. J. Sokoll, D. W. Chan, and I.-M. Shih Increased Plasma DNA Integrity in Cancer Patients Cancer Res., July 15, 2003; 63(14): 3966 - 3968. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Pisal, M. Sindos, and A. Singer Re: Assessment of Plasma DNA Levels, Allelic Imbalance, and CA 125 as Diagnostic Tests for Cancer J Natl Cancer Inst, February 19, 2003; 95(4): 331 - 331. [Full Text] [PDF]
|
|